Pharmafile Logo

Inovio

- PMLiVE

The Evolving Role of the Sales Rep

The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...

Avalere Health

- PMLiVE

FDA issues innovative proposal to increase nonprescription drug access

Nonprescription drugs provide an efficient, low-cost way to manage everyday health needs and include drugs for allergies, pain, fever and many more indications

- PMLiVE

Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine

Preliminary laboratory studies show both vaccines neutralise Omicron BA.4 and BA.5

- PMLiVE

Sanofi and GSK report positive data for COVID-19 Beta vaccine

Results from stage 1 and stage 2 of the study showed a favourable safety and tolerability profile

- PMLiVE

FDA grants Pfizer/BioNTech’s COVID-19 vaccine emergency use authorisation for infants

The authorisation is specifically for the children aged six months to four years

- PMLiVE

New virtual health and care report from WHO and Novartis calls for ‘critical action’

The report analysis shows how COVID-19 has changed virtual health and care policies in 23 countries

- PMLiVE

UK report suggests last winter’s Omicron strain was less likely to cause ‘long COVID’

Data from nearly 100,000 people was gathered by a team from King’s College London

- PMLiVE

EU governments pressure manufacturers to renegotiate contracts for COVID-19 vaccines

EU officials have warned that millions of vaccine doses could be wasted due to over-supply

- PMLiVE

Eli Lilly and Incyte’s Olumiant receives FDA approval for alopecia

The treatment is the first and only systemic medicine for adults with the condition

- PMLiVE

Sanofi and GSK share positive data for two COVID-19 booster vaccine trials

Both the COVIBOOST and phase 3 VAT02 trials showed the booster was well-tolerated, with favourable safety profiles

- PMLiVE

Sanofi and GSK share positive data for two COVID-19 booster vaccine trials

Both the COVIBOOST and phase 3 VAT02 trials showed the booster was well-tolerated, with favourable safety profiles

- PMLiVE

Moderna announces trial results for new COVID-19 booster vaccine candidate

The new vaccine candidate offers nearly twice as much protection against Omicron as Spikevax

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links